References
- Chadha P, Rademaker AW, Mendiratta P, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241–246.
- Else M, Ruchlemer R, Osuji N, Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2242–2248.
- Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
- Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–1896.
- Tallman MS, Hakimian D, Kopecky KJ, Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999;5:1665–1670.
- Hakimian D, Tallman MS, Kiley C, Peterson L. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993;82:1798–1802.
- Arons E, Margulies I, Sorbara L, Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 2006;12:2804–2811.
- Filleul B, Delannoy A, Ferrant A, A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994;8:1153–1156.
- Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 2006;125:251–259.
- Bengio R, Narbaitz MI, Sarmiento MA, Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000;85:1227–1229.
- Sausville JE, Salloum R, Sorbara L, Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213–217.
- Wheaton S, Tallman MS, Hakimian D, Peterson LC. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87:1556–1560.
- Bastie JN, Cazals-Hatem D, Daniel MT, Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999;35:555–565.
- Mhawech-Fauceglia P, Overholzer M, Aschenafi S, Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 2006;130:374–377.
- Ravandi F, Jorgensen JL, O'Brien SM, Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
- Cervetti G, Galimberti S, Andreazzoli F, Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004;73:412–417.
- Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983;61:349–352.
- Taniguchi N, Kuratsuna H, Kanamaru A, Inhibition against CFU-C and CFU-E colony formation by soluble factor(s) derived from hairy cells. Blood 1989;73:907–913.
- Else M, Osuji N, Forconi F, The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110: 2240–2247.
- Kraitman RJ, Stetler-Stevenson M, Margulies I, Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983–2990.
- Matutes E, Meeus P, McLennan K, Catovsky D. The significance of minimal residual disease in hairy cell leukemia treated with deoxycoformycin:a long-term follow-up study. Br J Haematol 1997;98:375–383.
- Konwalinka G, Schirmer M, Hilbe W, Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine. Blood Cells Mol Dis 1995;21:142–151.